Novel Nasal Drug Delivery device

OptiNose has developed innovative nasal drug delivery devices that enable nasal administration of CNS (nose to brain), systemic and topical nasal formulations. OptiNose’s unique breath actuated devices deliver intranasal drugs to targeted regions of the nasal cavity, including the sinuses and the olfactory region, without lung deposition, unlike traditional nasal inhalers, nasal sprays or nebulizers. The Company offers both single and multi-use intranasal delivery devices for liquid and powder formulations. Founded in 2000, OptiNose has extensively tested the technology in both in-vitro and in-vivo deposition studies and concluded Phase I studies. The Company has recently completed Phase II clinical studies with rhinosinusitis and migraine therapies.

Pharmaceutical and biotech companies interested in evaluating the rhinosinusitis or migraine applications, or seeking an innovative delivery platform for their proprietary CNS, systemic, or topical nasal compounds should contact OptiNose. CLICK HERE.

BUSINESS DEVELOPMENT OPPORTUNITIES

news & publications

	20 September 2008 - Upcoming E... 18.07.2008
	American Headache Society - Ph... 29.06.2008
	OptiNose Presents Data on High... 29.06.2008
	American Academy of Neurology ... 18.04.2008
	OptiNose Nasal Delivery of Sum... 18.04.2008
	Phase I Human Insulin Data ... 23.03.2008
	news & publication archive...